4,620 Shares in Edwards Lifesciences Co. (NYSE:EW) Bought by Sanders Morris Harris LLC

Sanders Morris Harris LLC purchased a new position in shares of Edwards Lifesciences Co. (NYSE:EW) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 4,620 shares of the medical research company’s stock, valued at approximately $424,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in EW. Castleview Partners LLC bought a new stake in shares of Edwards Lifesciences in the 1st quarter worth about $25,000. Core Alternative Capital increased its position in shares of Edwards Lifesciences by 96.1% in the 1st quarter. Core Alternative Capital now owns 353 shares of the medical research company’s stock worth $29,000 after purchasing an additional 173 shares during the last quarter. Compass Wealth Management LLC bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth about $31,000. Jones Financial Companies Lllp bought a new stake in shares of Edwards Lifesciences in the 1st quarter worth about $33,000. Finally, MCF Advisors LLC increased its position in shares of Edwards Lifesciences by 179.6% in the 1st quarter. MCF Advisors LLC now owns 411 shares of the medical research company’s stock worth $34,000 after purchasing an additional 264 shares during the last quarter. Hedge funds and other institutional investors own 79.25% of the company’s stock.

Insider Buying and Selling

In related news, insider Larry L. Wood sold 8,660 shares of the business’s stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $73.63, for a total value of $637,635.80. Following the sale, the insider now directly owns 213,794 shares in the company, valued at approximately $15,741,652.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Larry L. Wood sold 8,660 shares of the business’s stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $73.63, for a total value of $637,635.80. Following the sale, the insider now directly owns 213,794 shares in the company, valued at approximately $15,741,652.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 4,500 shares of the business’s stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $73.71, for a total transaction of $331,695.00. Following the completion of the sale, the vice president now owns 39,503 shares in the company, valued at $2,911,766.13. The disclosure for this sale can be found here. Insiders have sold 174,359 shares of company stock worth $14,301,522 in the last ninety days. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Trading Down 1.1 %

Shares of NYSE:EW opened at $73.20 on Friday. The company has a 50 day moving average of $81.38 and a 200-day moving average of $83.95. The firm has a market cap of $44.50 billion, a P/E ratio of 32.39, a P/E/G ratio of 3.95 and a beta of 1.03. Edwards Lifesciences Co. has a twelve month low of $67.13 and a twelve month high of $94.87. The company has a current ratio of 3.15, a quick ratio of 2.30 and a debt-to-equity ratio of 0.09.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Wednesday, July 26th. The medical research company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.01. The company had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.51 billion. Edwards Lifesciences had a net margin of 24.56% and a return on equity of 25.43%. The business’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.63 EPS. As a group, analysts anticipate that Edwards Lifesciences Co. will post 2.55 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on EW. Truist Financial boosted their target price on shares of Edwards Lifesciences from $101.00 to $105.00 in a research report on Wednesday, July 19th. Robert W. Baird began coverage on shares of Edwards Lifesciences in a research report on Tuesday, July 18th. They set an “outperform” rating and a $107.00 price objective for the company. Jefferies Financial Group boosted their price objective on shares of Edwards Lifesciences from $103.00 to $107.00 and gave the company a “buy” rating in a research report on Tuesday, July 25th. Morgan Stanley reaffirmed an “overweight” rating and set a $102.00 price objective on shares of Edwards Lifesciences in a research report on Friday, July 14th. Finally, Piper Sandler lowered their price objective on shares of Edwards Lifesciences from $88.00 to $83.00 and set a “neutral” rating for the company in a research report on Friday, September 8th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Hold” and a consensus target price of $92.42.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.